FDA Discusses Manufacturing Processes In ARB Medicines Impurities Update

Manufacturers using processes at risk for impurities in ARB medicines are expected to complete tests to ensure that active ingredients and finished products are free of detectable levels of nitrosamine impurities, the FDA has directed.

Flashlight
FDA's investigations point to changes in manufacturing processes potentially leading to impurities • Source: Shutterstock

More from Generics

More from Products